secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001628280-26-022006
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing
--------------------------------------------------------------------------------

- Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).
- Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.
- Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.
- Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.
- Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/sgmo-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-022006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer